A real world study suggests found that more than three-quarters of participants receiving the anti-amyloid drug Leqembi ...
The platform, known as the NULISAseq CNS Disease 120 Panel, was developed by Alamar Biosciences. It uses proximity extension ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results